Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Silma
Elektrostal, Moscow Oblast, Russiaenterosgel.ru ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TNC SILMA is a pharmaceutical company primarily known for the development and manufacture of Enterosgel, an innovative organosilicon-based intestinal adsorbent. The company's flagship product, Enterosgel (polymethylsiloxane polyhydrate), is used globally for the detoxification of the body, treating conditions such as acute and chronic diarrhea, allergies, and various gastrointestinal disorders. TNC SILMA operates in both the medical and veterinary sectors, providing original products based on its proprietary organosilicon technology. The company has a significant international presence, with its products registered and sold in over 40 countries across Europe, Asia, and the CIS region.
- Therapeutic areas
- ImmunologyOtherGastroenterology
- Modalities
- Small moleculeOrganosilicon polymer
- Industry
- Biotech
Beyond the preview
Go deeper on Silma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Silma.